Cd28 Induces Metabolic Fitness In Multiple Myeloma For Ros-Dependent Survival

Multiple myeloma (MM) is a hematological malignancy of bone marrow resident plasma cells. Although patient outcomes have improved with new classes of proteasome inhibitors, immunomodulatory drugs, and targeted monoclonal antibodies, the disease remains largely incurable. Understanding the mechanisms by which resistant myeloma cells are able to survive is critical for the development of therapeutic strategies to prevent patient relapse.